| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.10. | Earnings roundup: Lilly's unwavering momentum, Novartis' rebound and GSK's waiting game | ||
| 29.10. | Labor Department finalizes sweeping PBM disclosure rule | ||
| 29.10. | Genmab soars to record highs after cancer drug succeeds in key trial | ||
| 29.10. | HHS to allow compounders to make 6 unapproved peptides | ||
| 29.10. | Flagship blends three biotech startups to form Etcelera | ||
| 28.10. | Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial | ||
| 28.10. | FDA unveils guidance for 'plug and play' gene therapies | ||
| 28.10. | Lilly shuffles business structure; Novartis writes off part of Avidity deal | ||
| 27.10. | Ferring to acquire next-gen IVF startup Gameto for up to $1.4B | ||
| 27.10. | Court rejects Novo bid to block Lilly obesity drug ads | ||
| 27.10. | Artiva to quit autoimmune cell therapy work, cut staff after patient deaths | ||
| 26.10. | Corxel, an obesity drugmaker, to go public via SPAC deal | ||
| 26.10. | BioNTech, DualityBio say ADC had 'modest' benefit in breast cancer study | ||
| 26.10. | ESMO '26: A cancer vaccine debate, Roche's KRAS progress and Amgen's 'unprecedented' data | ||
| 26.10. | Another autoimmune CAR-T death; Treasury zeroes in on China deals | ||
| 26.10. | The molecule was fine. The moment wasn't. | ||
| 26.10. | Novel protein and peptide therapeutics | ||
| 23.10. | This week in charts: a big year for RNAi developers | ||
| 23.10. | Star adds $200M after spinout successes | ||
| 22.10. | Moderna, Merck shares fall on eagerly anticipated cancer vaccine results | ||
| 22.10. | Biohaven's previously rejected rare disease drug to get fresh FDA review | ||
| 22.10. | GLP-1 compounder issues recall for copycat Zepbound | ||
| 22.10. | Roche affirms sales outlook amid doubts about its future | ||
| 21.10. | GSK, Ionis win US approval for first-of-its-kind hepatitis B drug | ||
| 21.10. | Roivant, continuing ascent, claims another victory for rare disease drug |